DXD:NYE-ProShares UltraShort Dow30

ETF | Drug Manufacturers | NYE

Last Closing Price

USD 25.73


+0.06 (+0.23)%

Market Cap

USD 0.16B



Average Target Price

Average Analyst Rating


STA Verdict



The investment seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Dow Jones Industrial Average® Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a price-weighted index and includes 30 large-cap, blue-chip U.S. stocks, excluding utility and transportation companies. The fund is non-diversified.

Inception Date: 11/07/2006

Primary Benchmark: DJ Industrial Average TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.95%

Management Expense Ratio: 0.95 %

Market Stats

Unadjusted Closing Price

Adjusted Closing Price



Top Sectors


Top Regions


Valuation Growth & Performance

Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2019-10-22 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SSO ProShares Ultra S&P500 0.90 %

-0.97 (-0.74%)

USD 2.40B
QLD ProShares Ultra QQQ 0.95 %

-1.62 (-1.60%)

USD 1.90B
UYG ProShares Ultra Financials 0.95 %

-0.66 (-1.37%)

USD 0.80B
PSQ ProShares Short QQQ 0.95 %

+0.21 (+0.78%)

USD 0.50B
DDM ProShares Ultra Dow30 0.95 %

-0.12 (-0.24%)

USD 0.36B
DOG ProShares Short Dow30 0.95 %

+0.07 (+0.13%)

USD 0.22B
UWM ProShares Ultra Russell2000 0.95 %

+0.04 (+0.06%)

USD 0.17B
MVV ProShares Ultra MidCap400 0.95 %

-0.03 (-0.07%)

USD 0.14B
URE ProShares Ultra Real Estate 0.95 %

-0.70 (-0.77%)

USD 0.14B
EUO ProShares UltraShort Euro 0.95 %

+0.10 (+0.37%)

USD 0.13B

ETFs Containing DXD

Symbol Name Weight Mer Price(Change) Market Cap


Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain -27.32% 16% F 7% F
Dividend Return 0.87% 53% F 16% F
Total Return -26.45% 16% F 7% F
Trailing 12 Months  
Capital Gain -17.45% 18% F 18% F
Dividend Return 1.45% 71% C- 26% F
Total Return -16.00% 18% F 17% F
Trailing 5 Years  
Capital Gain -75.24% 6% F 6% F
Dividend Return 0.73% 23% F 4% F
Total Return -74.51% 9% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -22.98% 5% F 3% F
Dividend Return 0.37% 38% F 10% F
Total Return -22.60% 5% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 13.35% 66% D 59% F
Risk Adjusted Return -169.28% 8% F 1% F
Market Capitalization 0.16B 82% B- 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.